← Eichor
Study identifier: NCT07611136 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Cerebral Small Vessel Disease Progression Dependent on Stroke Type

Condition: Cerebral Small Vessel Disease · Stroke · Stroke Recurrence  ·  Sponsor: Johannes Dorst

PhaseN/A
Planned participants180
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this prospective, observational study is to understand if cerebral small vessel disease (CSVD) has different velocities and patterns of temporal development, dependent on a concurrent ischemic stroke. It focusses on adult patients with known or newly diagnosed CSVD on magnetic resonance imaging. The study will evaluate if blood based, in parts central nervous system specific protein markers, so called biomarkers, have an additional value reflecting the course of CSVD as defined per MRI assessments. Further patient-relevant endpoints include neuropsychological abilities, neurological functional outcomes, quality of life assessments, stroke recurrence risk.

This description comes directly from the study's public registry record.

Talk to the study team

Mona E Laible, MD  ·  +49(0)7311770  ·  mona.laible@uniklinik-ulm.de

Always discuss trial participation with your own doctor first.

Locations (1)

University Hospital Ulm, Department of Neurology, GermanyUlm, Baden-Wurttemberg, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07611136